

WHAT IS CLAIMED IS:

Sub  
a' 1. A composition comprising a live attenuated *Streptococcus equi*  
2 and an immunostimulant, said immunostimulant having the property of stimulating  
3 mucosal immunity.

c 1 2. The composition of claim 1, wherein said *Streptococcus equi* is  
2 non-encapsulated.

c 1 3. The composition of claim 1, wherein said immunostimulant is  
2 saponin, metabolizable oil, bacterial toxoid, bacterial adjuvant, interleukin, interferon,  
3 carbopol, dextran derivative, dimethyldioctadecylammonium bromide or a mixture  
4 thereof.

c 1 4. The composition of claim 1, wherein said immunostimulant is  
2 saponin.

a 1 5. The composition of claim 1, wherein said *Streptococcus equi* is  
2 strain 709-27<sub>A</sub> (ATCC 53186)

Sub #2 6. The composition of claim 4, wherein said saponin is in the  
2 amount of from about 1 to about 10 mg/ml of said composition.

1 7. The composition of claim 4, wherein said saponin is in the  
2 amount of from about 3 to about 7 mg/ml of said composition.

1 8. The composition of claim 4, wherein said saponin is in the  
2 amount of from about 4 to about 6 mg/ml of said composition.

a 1 9. The composition of claim 1, wherein said *Streptococcus equi* is  
2 strain 709-27<sub>A</sub> (ATCC 53186) and said immunostimulant is saponin.

090073. "01 598  
865 TO "E20060

- 1 10. A dosage form for nasal administration comprising the  
2 composition of claim 1.

- 1 *See E3* 11. The dosage form of claim 10, wherein said *Streptococcus equi* is  
2 strain 709-27<sub>A</sub> and said immunostimulant is saponin.  
(ATCC 53186)

- 1 *See 32* 12. The dosage form of claim 11, wherein said *Streptococcus equi* is  
2 present in a maximum dose of about  $1 \times 10^9$ .

- 1 13. The dosage form of claim 11, wherein said *Streptococcus equi* is  
2 present in a minimum dose of about  $1.7 \times 10^7$ .

- 1 *See E4* 14. The dosage form of claim 11 wherein said *Streptococcus equi* is  
2 in a lyophilized form and said saponin is in a diluent.

- 1 15. A method of stimulating an immune response to *Streptococcus*  
2 *equi* comprising contacting cells of the nasopharyngeal mucosa of an equine with a  
3 composition of claim 1.

- 1 *See E5* 16. The method of claim 15, wherein said *Streptococcus equi* is  
2 strain 709-27<sub>A</sub> and said immunomodulator is saponin.  
(ATCC 53186)

- 1 17. A method for preventing at least one of the symptoms associated  
2 with *Streptococcus equi* infection in equine comprising administering an effective  
3 amount of the composition of claim 1 nasally or by mouth to said equine.

- 1 *See E6* 18. The method of claim 17, wherein said *Streptococcus equi* is  
2 strain 709-27<sub>A</sub> and said immunomodulator is saponin.  
(ATCC 53186)

- 1 *See E6* 19. The method of claim 17, wherein said attenuated *Streptococcus*  
2 *equi* is in the amount of from about  $10^5$  to about  $10^{11}$  CFU.  
Colony forming Unit (CFU)

1                    20.    The method of claim 17, wherein said attenuated *Streptococcus*  
 2 *equi* is in the amount of from about  $10^6$  to about  $10^{10}$  <sup>Colony Forming Unit (CFU)</sup> <sub>CFU</sub>.

1                    21.    The method of claim 17, wherein said attenuated *Streptococcus*  
 2 *equi* is in the amount of from about  $10^7$  to about  $10^9$  <sup>Colony Forming Unit (CFU)</sup> <sub>CFU</sub>.

add 17

09007385-011598